News Releases

Servier completes the acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business

Servier Presentations at ISPNO 2026 Highlight Neuro-Oncology Leadership and Expanding Glioma Portfolio

Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.

Promising Phase 1 Data for Servier's Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026

Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business

Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026

Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio

Emiltatug Ledadotin (Emi-Le) Granted Breakthrough Therapy Designation by the U.S. FDA for Adenoid Cystic Carcinoma (ACC)

Day One and Servier Complete Enrollment in Pivotal Phase 3 FIREFLY-2 Trial of Tovorafenib as a Front-Line Treatment for Pediatric Low-Grade Glioma (pLGG)

Servier completes the acquisition of Day One Biopharmaceuticals

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030

Servier's Clinical and Real-World Data at 2025 SNO Congress Showcase Leadership in IDH-Mutant Glioma

Servier's New and Updated Data at 2025 ASH Annual Meeting Highlight Commitment to Hematology Research

Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology

Servier's VORANIGO® (vorasidenib) Receives Prestigious 2025 Prix Galien USA Award

European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide

Servier’s VORANIGO® (vorasidenib) Nominated for 2025 Prix Galien USA Award

Servier Announces Positive Data from Long-Term Follow-Up Analysis of the Phase 3 AGILE Trial of TIBSOVO® (ivosidenib) in IDH1-mutated Acute Myeloid Leukemia

Servier Receives Positive CHMP Opinion for VORANIGO® (vorasidenib) for the Treatment of Adults and Adolescents with Grade 2 IDH-mutant Diffuse Glioma

Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey

Servier Presentations at ASCO 2025 Reinforce Company Leadership in IDH-Mutated Cancers

Servier announces the appointment of Nitza Thomasson as Executive Director R&D Neurology

Servier Appoints David K. Lee to Executive Committee

Servier Announces Expansion of its Tibsovo (ivosidenib) Development Program Investigating its Safety and Efficacy in Patients Living with IDH1-Mutated Cancers in Both Hematological Malignancies and Solid Tumors

Servier Partners With Local Cancer Center to Support Research Graduate Students in the Boston Area

Servier to Present Data Across its Hematology Portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting

Servier to Present Data on IDH-mutant Glioma at the 2024 Society for Neuro-Oncology (SNO) Congress

Servier's VORANIGO® (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant Glioma

Servier Initiates Critical Dialogue on AYA Cancer Survivorship at ASCO 2024

Servier Highlights Commitment to Improving Cancer Outcomes at ASCO 2024

Servier Ranks 1st Across Several Categories in 2023-2024 PatientView U.S. Corporate Reputation Survey

Servier Data Presented at AACR Underscores Unwavering Dedication to Advancing Oncology R&D

Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma

FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma

CStone sells to Servier its exclusive rights to TIBSOVO®in Greater China and Singapore

Servier Showcases Leadership in Mutant Isocitrate Dehydrogenase (IDH) Inhibition Through New Data Spotlighting Real-World Treatment Patterns and Clinical Outcomes of Tibsovo® Use at ASH 2023

Servier Expands Base4 Partnership to Advance Neuroscience Drug Development

Nicolas Garnier joins Servier as Chief Patient Officer

Servier Data at ASH 2023 Furthers Leadership in Hard-to-Treat Hematologic Malignancies

Data at ASH 2023 Underscores Servier Leadership in Hard-to-Treat Hematologic Malignancies

New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib's Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma

New Vorasidenib Data at SNO 2023 Bolster Servier's Neuro-Oncology Clinical Development Program

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)

Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in the Treatment of IDH1-mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)

Servier Presents Updated Results for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Relapsed/Refractory Myelodysplastic Syndromes at the 2023 European Hematology Association (EHA) Congress

Servier Bolsters Position as the Leader in Mutant IDH Inhibition with Positive New IDH1-Mutated Acute Myeloid Leukemia Data at ASCO

Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma